Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKesson
Queensland Health
Fuji
Johnson and Johnson
Deloitte
Harvard Business School
Moodys

Generated: June 25, 2018

DrugPatentWatch Database Preview

OCUFEN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Ocufen, and when can generic versions of Ocufen launch?

Ocufen is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in OCUFEN is flurbiprofen sodium. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the flurbiprofen sodium profile page.
Drug patent expirations by year for OCUFEN
Synonyms for OCUFEN
(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, sodium salt
2-Fluoro-alpha-methyl-4-diphenylacetic acid sodium salt
56767-76-1
8308AB
AF10211
AN-40130
AUAGTGKMTMVIKN-UHFFFAOYSA-M
C15H12FNaO2
CHEMBL1200990
EINECS 260-373-2
FLURBIPROFEN SODIUM
Flurbiprofen sodium [USAN]
Flurbiprofen sodium [USP]
Flurbiprofen sodium salt
KB-51899
LS-44096
RL04144
SCHEMBL4735171
sodium 2-(2-fluorobiphenyl-4-yl)propanoate
sodium 2-(3-fluoro-4-phenyl-phenyl)propanoate
Sodium 2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetate
Sodium 2-fluoro-alpha-methyl(1,1'-biphenyl)-4-acetate
Sodium 2-fluoro-alpha-methyl[1,1'-biphenyl]-4-acetate
Sodium 3-fluoro-4-phenylhydratropate
Sodium flurbiprofen
Sodiumflurbiprofen

US Patents and Regulatory Information for OCUFEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan OCUFEN flurbiprofen sodium SOLUTION/DROPS;OPHTHALMIC 019404-001 Dec 31, 1986 AT RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for OCUFEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan OCUFEN flurbiprofen sodium SOLUTION/DROPS;OPHTHALMIC 019404-001 Dec 31, 1986 ➤ Sign Up ➤ Sign Up
Allergan OCUFEN flurbiprofen sodium SOLUTION/DROPS;OPHTHALMIC 019404-001 Dec 31, 1986 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Dow
Cantor Fitzgerald
AstraZeneca
UBS
Covington
Chinese Patent Office
QuintilesIMS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.